Grit Biotechnology Secures RMB 400 Million Series B Financing Led by CICC Capital to Advance TIL-based Cancer Immunotherapies

This round of financing will be used to support the development of the company's tumor-infiltrating lymphocyte (TIL) therapy pipeline, including the pivotal clinical trial of GT101 and the development of multiple next-generation gene-edited TIL pipelines, aiming to create groundbreaking cell therapies for patients with solid tumors worldwide.

Grail Bio was founded in 2019 as an innovative pharmaceutical company focusing on tumor immunotherapy and TIL drug development pipelines. GT101 Injection, independently developed by Grail Bio, is the first TIL drug in China to be approved for clinical trials, and it is about to enter a pivotal Phase II clinical trial. The company's core R&D platforms include the StemTexp® TIL expansion technology platform, StaViral® stable virus production process, ImmuT Finder® immunomodulatory target discovery platform, and KOReTIL® efficient gene knockout system, based on which a series of next-generation gene-edited TIL drugs have been developed. Grail Bio boasts world-leading technical reserves and industry resources, aiming to create groundbreaking solid tumor cell therapies that bring new hope to cancer patients.

"We are very pleased to have the support and recognition from well-known investment institutions in the industry and our existing shareholders. We will accelerate the clinical work of our leading pipeline GT101 and achieve product commercialization as soon as possible."Dr. Yarong Liu, Co-founder and CEO of Gracell Biotechnologies"Sagittarius Bio always adheres to the values of perseverance, integrity, focus, and care, as well as the vision of allowing cancer patients to regain the joy of life, continuously providing world-class cell therapy products to patients worldwide."